TWI904906B - Sarm1之抑制劑 - Google Patents

Sarm1之抑制劑

Info

Publication number
TWI904906B
TWI904906B TW113140249A TW113140249A TWI904906B TW I904906 B TWI904906 B TW I904906B TW 113140249 A TW113140249 A TW 113140249A TW 113140249 A TW113140249 A TW 113140249A TW I904906 B TWI904906 B TW I904906B
Authority
TW
Taiwan
Prior art keywords
compound
dissolved
substituted
mmol
methanol
Prior art date
Application number
TW113140249A
Other languages
English (en)
Chinese (zh)
Other versions
TW202530197A (zh
Inventor
陶德 波薩納克
拉杰什 德芙拉吉
羅伯特 歐文 修斯
安德鲁 布雷利
派克 理查 安德魯 傑瑞斯
雪莉 安妮 帕勒特
Original Assignee
美商達薩瑪治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商達薩瑪治療公司 filed Critical 美商達薩瑪治療公司
Publication of TW202530197A publication Critical patent/TW202530197A/zh
Application granted granted Critical
Publication of TWI904906B publication Critical patent/TWI904906B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
TW113140249A 2020-08-24 2021-08-20 Sarm1之抑制劑 TWI904906B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063069408P 2020-08-24 2020-08-24
US63/069,408 2020-08-24
US202163142398P 2021-01-27 2021-01-27
US63/142,398 2021-01-27

Publications (2)

Publication Number Publication Date
TW202530197A TW202530197A (zh) 2025-08-01
TWI904906B true TWI904906B (zh) 2025-11-11

Family

ID=77775005

Family Applications (3)

Application Number Title Priority Date Filing Date
TW113140249A TWI904906B (zh) 2020-08-24 2021-08-20 Sarm1之抑制劑
TW110130799A TWI786777B (zh) 2020-08-24 2021-08-20 Sarm1之抑制劑
TW111144632A TW202334117A (zh) 2020-08-24 2021-08-20 Ｓａｒｍ１之抑制劑

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110130799A TWI786777B (zh) 2020-08-24 2021-08-20 Sarm1之抑制劑
TW111144632A TW202334117A (zh) 2020-08-24 2021-08-20 Ｓａｒｍ１之抑制劑

Country Status (21)

Country Link
US (2) US12043613B2 (https=)
EP (1) EP4200293A1 (https=)
JP (2) JP7349046B2 (https=)
KR (2) KR20260016617A (https=)
AU (2) AU2021333558C1 (https=)
BR (1) BR112023002575A2 (https=)
CA (1) CA3189181A1 (https=)
CL (1) CL2023000525A1 (https=)
CO (1) CO2023001975A2 (https=)
CR (1) CR20230113A (https=)
DO (1) DOP2023000038A (https=)
EC (1) ECSP23012981A (https=)
IL (1) IL300586A (https=)
JO (1) JOP20230037A1 (https=)
MX (1) MX2023002256A (https=)
NZ (1) NZ797733A (https=)
PE (1) PE20230737A1 (https=)
TW (3) TWI904906B (https=)
UA (1) UA130657C2 (https=)
WO (1) WO2022046606A1 (https=)
ZA (1) ZA202301801B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
US12404265B2 (en) * 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
CN116438171A (zh) 2020-09-16 2023-07-14 努拉生物公司 作为sarm1抑制剂的取代的吡啶衍生物
EP4376840A4 (en) 2021-07-28 2025-05-21 Nura Bio, Inc. SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
US20240102018A1 (en) * 2022-07-21 2024-03-28 Amylyx Pharmaceuticals, Inc. Oligonucleotide compositions and methods thereof
IL321043A (en) * 2022-12-15 2025-07-01 Sironax Ltd SARM1 modulators, their preparations and uses
EP4655069A1 (en) 2023-01-24 2025-12-03 Disarm Therapeutics, Inc. Pyridazines as sarm1 inhibitors
TW202509019A (zh) * 2023-04-27 2025-03-01 香港商維泰瑞隆（香港）生物科技有限公司 Sarm1調節子、其製劑及用途
CN119219603A (zh) * 2023-06-28 2024-12-31 科辉智药(深圳)新药研究中心有限公司 Sarm1酶活性抑制剂及其用途
CN121712761A (zh) * 2023-08-25 2026-03-20 豪夫迈·罗氏有限公司 用于治疗神经退行性病症的作为sarm1抑制剂的吡唑衍生物
IL326761A (en) 2023-08-25 2026-04-01 Lilly Co Eli (S)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate
WO2025076088A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Lactams for use as sarm1 inhibitors
WO2025076017A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Carbamates for use as sarm1 inhibitors
TW202545928A (zh) 2024-01-25 2025-12-01 比利時商優稀美生物醫藥股份有限公司 吡咯啶酮衍生物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018114662A1 (de) * 2016-12-22 2018-06-28 Bayer Cropscience Aktiengesellschaft Substituierte 1,2,4-thiadiazolylpyrrolone und 1,2,4-thiadiazolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe
WO2019236890A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436966B1 (en) 1997-10-27 2002-08-20 Takeda Chemical Ind., Ltd. Adenosine A3 receptor antagonists
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
AR043057A1 (es) 2002-10-30 2005-07-13 Vertex Pharma Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa
AU2003300099A1 (en) 2003-01-02 2004-07-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2005105780A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
US8101770B2 (en) 2004-12-16 2012-01-24 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
EP2036905B1 (en) 2006-06-28 2012-12-12 ASKA Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
CA2662359A1 (en) 2006-09-21 2008-03-27 Novartis Ag Pyrrole derivatives useful for the treatment of cytokine-mediated diseases
EP2240475B1 (en) 2007-12-20 2013-09-25 Novartis AG Thiazole derivatives used as pi 3 kinase inhibitors
JP2011506563A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー ビスチアゾール誘導体、その製造方法および医薬品としてのその使用
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
WO2012178022A2 (en) 2011-06-24 2012-12-27 University Of Massachusetts Therapeutic applications targeting sarm1
WO2014070978A1 (en) 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
US9695198B2 (en) 2012-12-19 2017-07-04 Merck Sharp & Dohme Corp. Factor IXa inhibitors
RU2570907C2 (ru) 2013-10-21 2015-12-20 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
WO2015084936A1 (en) 2013-12-04 2015-06-11 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
WO2018035204A1 (en) 2016-08-16 2018-02-22 Henry Ford Health System Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies
JP7044789B2 (ja) 2016-09-24 2022-03-30 ワシントン・ユニバーシティ Ｓａｒｍ１ ｎａｄアーゼ活性の阻害剤およびその使用
WO2018107056A1 (en) 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels
EP3558976A1 (de) 2016-12-22 2019-10-30 Bayer CropScience Aktiengesellschaft Substituierte azolylpyrrolone und azolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe
US11919902B2 (en) * 2017-12-22 2024-03-05 Hibercell, Inc. Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
CN112839647B (zh) 2018-06-07 2025-09-23 达萨玛治疗公司 Sarm1抑制剂
CN112839648B (zh) * 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
US12084436B2 (en) * 2019-01-30 2024-09-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7289375B2 (ja) 2019-06-06 2023-06-09 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１の阻害剤
US12595252B2 (en) 2019-06-14 2026-04-07 Disarm Therapeutics, Inc. Inhibitors of SARM1
MX2022000950A (es) 2019-07-22 2022-02-14 Bayer Ag 5-amino pirazoles y triazoles como plaguicidas.
CA3150878A1 (en) 2019-09-12 2021-03-18 Jonathan Bentley Inhibitors of sarm1
WO2021092240A1 (en) 2019-11-05 2021-05-14 Dermira, Inc. Mrgprx2 antagonists for the treatment of inflammatory disorders
WO2021142006A1 (en) 2020-01-07 2021-07-15 Disarm Therapeutics, Inc. Inhibitors of sarm1
US12435084B2 (en) 2020-04-09 2025-10-07 Eli Lilly And Company Indazole derivatives as inhibitors of SARM1
US12606558B2 (en) 2020-04-09 2026-04-21 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of SARM1
US12404265B2 (en) * 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018114662A1 (de) * 2016-12-22 2018-06-28 Bayer Cropscience Aktiengesellschaft Substituierte 1,2,4-thiadiazolylpyrrolone und 1,2,4-thiadiazolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe
WO2019236890A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1

Also Published As

Publication number Publication date
WO2022046606A1 (en) 2022-03-03
DOP2023000038A (es) 2023-03-15
UA130657C2 (uk) 2026-04-08
KR20230057396A (ko) 2023-04-28
JP7756130B2 (ja) 2025-10-17
ECSP23012981A (es) 2023-03-31
IL300586A (en) 2023-04-01
JOP20230037A1 (ar) 2023-02-23
AU2021333558C1 (en) 2024-06-20
US20220056013A1 (en) 2022-02-24
US20240376083A1 (en) 2024-11-14
NZ797733A (en) 2026-03-27
AU2021333558A1 (en) 2023-03-02
EP4200293A1 (en) 2023-06-28
MX2023002256A (es) 2023-03-17
TWI786777B (zh) 2022-12-11
US12043613B2 (en) 2024-07-23
AU2021333558B2 (en) 2024-02-22
CR20230113A (es) 2023-04-14
JP7349046B2 (ja) 2023-09-21
JP2023535236A (ja) 2023-08-16
AU2024203373A1 (en) 2024-06-13
PE20230737A1 (es) 2023-05-03
ZA202301801B (en) 2024-09-25
CA3189181A1 (en) 2022-03-03
TW202334117A (zh) 2023-09-01
KR102918550B1 (ko) 2026-01-27
AU2024203373B2 (en) 2026-04-02
KR20260016617A (ko) 2026-02-03
CL2023000525A1 (es) 2023-09-15
CO2023001975A2 (es) 2023-03-07
TW202214597A (zh) 2022-04-16
BR112023002575A2 (pt) 2023-03-07
JP2024016014A (ja) 2024-02-06
TW202530197A (zh) 2025-08-01

Similar Documents

Publication Publication Date Title
TWI904906B (zh) Sarm1之抑制劑
CN115175900B (zh) Sarm1的抑制剂
CN114728007B (zh) Sarm1的抑制剂
JP7319395B2 (ja) Ｓａｒｍ１の阻害剤
CN116075511B (zh) 作为sarm1抑制剂的稠合吡唑衍生物
CN116568678B (zh) Sarm1的苯并吡唑抑制剂
CN115916764B (zh) 作为sarm1抑制剂的吲唑衍生物
WO2020076738A2 (en) Protein-binding compounds
HK40075925A (en) Inhibitors of sarm1
BR122025022748A2 (pt) Inibidores de sarm1, composições que os compreendem, usos dos mesmos, métodos para inibir sarm1, e combinações
CN116940569A (zh) Sarm1抑制剂
EA048703B1 (ru) Ингибиторы sarm1